Latest Audeara (ASX:AUA) News

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Audeara has locked in exclusive Australian rights to a customised assistive listening device from ShokzHear, aiming to tackle widespread listening challenges among schoolchildren through government-backed programs.

Audeara Ltd has posted its second straight quarter of positive operating cash flow, driven by a record Australian wholesale order and expanding technology licensing deals. The company’s cash balance rose to $1.05 million as it advances global market expansions.

Tech microcaps swung hard as funding news, contract wins and disclosure issues collided. The biggest falls came where investors saw either forced selling or more cash needs ahead.

Audeara Limited has initiated three new white-label Auracast™ programs with Clinico Inc., alongside launching its BT-03 Audio Broadcaster in Australia, marking a significant step in scaling its audio technology globally.

One microcap exploded higher on a tiny capital raise, while several software names were sold hard despite reporting growth. The week split cleanly between “cash in the bank” stories and “still burning cash” worries.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

A small-cap healthcare rally had a clear centre: distribution deals, US regulatory steps, and big cheques. Osteopore, Echo IQ and Anteris led the week, while a handful of names slipped despite solid operational updates.

A takeover offer lit up small caps, while one high-growth software name slid hard despite strong sector news. Resources dominated the winners list, but investors still punished dilution and discounted fundraisings.

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Audeara Limited has secured its largest-ever Australian wholesale purchase order worth $560,000, driving year-to-date wholesale revenues to $1.75 million and matching full FY25 figures. The company is also expanding manufacturing into China, signaling growing international ambitions.

Audeara Limited has achieved a key regulatory milestone with NMPA certification in China, paving the way for commercial launch of its hearing personalisation technology through a leading e-commerce brand. This approval supports the company’s strategy to generate scalable licensing revenue in a rapidly growing market.